Molecular Basis for CCRL2 Regulation of Leukocyte Migration
Open Access
- 10 December 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
Abstract
CCRL2 is a seven-transmembrane domain receptor that belongs to the chemokine receptor family. At difference from other members of this family, CCRL2 does not promote chemotaxis and shares structural features with atypical chemokine receptors (ACKRs). However, CCRL2 also differs from ACKRs since it does not bind chemokines and is devoid of scavenging functions. The only commonly recognized CCRL2 ligand is chemerin, a non-chemokine chemotactic protein. CCRL2 is expressed both by leukocytes and non-hematopoietic cells. The genetic ablation of CCRL2 has been instrumental to elucidate the role of this receptor as positive or negative regulator of inflammation. CCRL2 modulates leukocyte migration by two main mechanisms. First, when CCRL2 is expressed by barrier cells, such endothelial, and epithelial cells, it acts as a presenting molecule, contributing to the formation of a non-soluble chemotactic gradient for leukocytes expressing CMKLR1, the functional chemerin receptor. This mechanism was shown to be crucial in the induction of NK cell-dependent immune surveillance in lung cancer progression and metastasis. Second, by forming heterocomplexes with other chemokine receptors. For instance, CCRL2/CXCR2 heterodimers were shown to regulate the activation of β2-integrins in mouse neutrophils. This mini-review summarizes the current understanding of CCRL2 biology, based on experimental evidence obtained by the genetic deletion of this receptor in in vivo experimental models. Further studies are required to highlight the complex functional role of CCRL2 in different organs and pathological conditions.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro
- Ministero dell’Istruzione, dell’Universitàe della Ricerca
This publication has 54 references indexed in Scilit:
- The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defensesThe Journal of Experimental Medicine, 2012
- Chemerin and its receptors in leukocyte trafficking, inflammation and metabolismCytokine & Growth Factor Reviews, 2011
- Chemokine-like receptor 1 (CMKLR1) and chemokine (C–C motif) receptor-like 2 (CCRL2); Two multifunctional receptors with unusual propertiesExperimental Cell Research, 2011
- Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemiaMolecular Cancer, 2010
- Nonredundant role of CCRL2 in lung dendritic cell traffickingBlood, 2010
- Lipid-Cytokine-Chemokine Cascade Drives Neutrophil Recruitment in a Murine Model of Inflammatory ArthritisImmunity, 2010
- CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM‐BImmunology, 2010
- Human B cells express the orphan chemokine receptor CRAM-A/B in a maturation-stage-dependent and CCL5-modulated mannerImmunology, 2008
- Mast cell–expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxisThe Journal of Experimental Medicine, 2008
- Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritisArthritis Research & Therapy, 2007